ISSN:
1432-1440
Keywords:
Coenzyme Q10
;
Cardiomyopathy
;
Bioenergetics
;
Ejection fraction
;
Cardiac output
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Summary Coenzyme Q10 (CoQ10) is indispensable in mitochondrial bioenergetics and for human life to exist. 88/115 patients completed a trial of therapy with CoQ10 for cardiomyopathy. Patients were selected on the basis of clinical criteria,X-rays, electrocardiograms, echocardiography, and coronary angiography. Responses were monitored by ejection fractions, cardiac output, and improvements in functional classifications (NYHA). Of the 88 patients 75%–85% showed statistically significant increases in two monitored cardiac parameters. Patients with the lowest ejection fractions (approx. 10%–30%) showed the highest increases (115Δ%–210Δ%) and those with higher ejection fractions (50%–80%) showed increases of approx. 10Δ%–25Δ% on therapy. By functional classification, 17/21 in class IV, 52/62 in class III, and 4/5 in class II improved to lower classes. Clinical responses appeared over variable times, and are presumably based on mechanisms of DNA-RNA-protein synthesis of apoenzymes which restore levels of CoQ10 enzymes in a deficiency state. 10/21 (48%) of patients in class IV, 26/62 (42%) in class III, and 2/5 (40%) in class II had exceptionally low control blood levels of CoQ10. Clinical responses on therapy with CoQ10 appear maximal with blood levels of approx. 2.5 µg CoQ10/ml and higher during therapy.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF01720833
Permalink
